Duration of Response and Progression-Free Survival with Sonidegib 200 Mg Once Daily Until Disease Progression or Start of New Antineoplastic Therapy in Patients with Locally Advanced Basal Cell Carcinoma: Results of the 42-Month, Randomized, Double-Blind
Main Article Content
Keywords
Basal Cell carcinoma, Sonidegib, duration of response
Abstract
References
2) Asgari MM, et al. JAMA Dermatol. 2015; 151:976–81
3) Amici JM, et al. Eur J Dermatol. 2015; 25:586–94
4) Lear JT, et al. Br J Cancer. 2014; 111:1476–81
5) Cortes JE, et al. Cancer Treat Rev. 2019; 76:41–50
6) Kim JYS, et al. J Am Acad Dermatol. 2018; 78:540–59
7) Odomzo (sonidegib) [package insert]. Cranbury, NJ: Sun Pharmaceutical Industries, Inc.; 2017
8) European Medicines Agency. Summary of Product Characteristics, WC500188762
9) Swissmedic, Authorization Number 65065, 2015
10) Australian Government Department of Health, ARTG 292262
11) Migden MR, et al. Lancet Oncol. 2015; 16:716–28
12) Migden MR, et al. J Clin Oncol. 2018; 36:Suppl abstr 9551
13) Lear JT, et al. J Eur Acad Dermatol Venereol. 2018; 32:372–81
14) Dummer R, et al. J Am Acad Dermatol. 2016; 75:113–25.E115
15) Dummer R, et al. Br J Dermatol. 2019; 10.1111/bjd.18552
16) Eisenhauer EA, et al. Eur J Cancer. 2009; 45 (2): 228–47
17) World Health Organization. http://whqlibdoc.who.int/offset/WHO_OFFSET_48.pdf
18) National Cancer Institute. https://evs.nci.nih.gov/ftp1/CTCAE/CTCAE_4.03/Archive/CTCAE_4.0_2009-05-29_QuickReference_8.5x11.pdf.
Article Sidebar
Article Details
This work is licensed under a Creative Commons Attribution 4.0 International License.
Creative Commons Attribution (CC BY): lets others distribute and copy the article, to create extracts, abstracts, and other revised versions, adaptations or derivative works of or from an article (such as a translation), to include in a collective work (such as an anthology), to text or data mine the article, even for commercial purposes, as long as they credit the author(s), do not represent the author as endorsing their adaptation of the article, and do not modify the article in such a way as to damage the author's honor or reputation.
Authors retain copyright in their work and license the publisher to publish the content. The publisher is the National Society for Cutaneous Medicine, with production and publishing support provided by OJS, Open Journal Systems,see https://pkp.sfu.
Prior to January 2022, authors transferred copyright to the National Society for Cutaneous Medicine. However, all articles are freely available to anyone in the world. There are no subscription fees, page charges, or article processing charges.